ClinicalTrials.gg
CompletedNCT02632747Updated Jul 24, 2020Results posted

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

A Phase 2 interventional study of Empagliflozin and Placebo (matching empagliflozin) in Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 and Obesity, sponsored by Boehringer Ingelheim. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-24.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 1.

Enrollment
9th of 12
31 · median 49
Started
2016
the only one that year
Phase 2
2 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
4 of 12
Boehringer Ingelheim

Among the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 2, and was the 4th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.

03

Conditions studied

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written .
  • Male or female patients diagnosed with type 1 diabetes (T1D) at least 6 months prior to informed consent or type 2 diabetes (T2D) or non-diabetic obese patients.
  • T1D patients must use and be willing of and be willing to continue throughout the duration of the trial either:
  • multiple daily injections of insulin OR
  • continuous sub-cutaneous insulin infusion of any insulin type, with at least 3 months experience
  • For patients with T1D or T2D, of 6.5 - 11%
  • Age at least 18 years of age
  • of >=18.5 kg/m\^2
  • Estimated greater than or equal to 60 ml/min/1.73m2
  • Blood pressure greater than 90 /60 mmHg and less than or equal to 140 / 90 mmHg
  • Use of a highly effective method of .
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • For patients with T1D, treatment with an antihyperglycaemic agent within 3 months prior to visit 1
  • occurrence of severe hypoglycaemia within 3 months prior to visit 1
  • hypoglycaemic unawareness within 3 months prior to visit 1
  • occurrence of diabetic ketoacidosis within 3 months of visit 1 and until visit 3 Further exclusion criteria apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Sequence A

    Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.

    Drug: Empagliflozin · Drug: Placebo (matching empagliflozin) · Drug: ramipril

  • Experimental
    Sequence B

    Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.

    Drug: Empagliflozin · Drug: Placebo (matching empagliflozin) · Drug: ramipril

Interventions

  • Empagliflozin will be taken once daily

  • DrugPlacebo (matching empagliflozin)

    Placebo will be taken once daily

  • Ramipril will be taken once or twice daily

06

What researchers measure

Primary outcomes

  1. Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.

    Glomerular filtration rate (GFR) under euglycaemic conditions after 4 weeks of treatment with either empagliflozin added to ramipril or placebo added to ramipril. The pre-specified statistical analysis was not conducted, because data are too sparse in the subgroup of hyperfilterers.

    Time frame: At week 4 and at week 12

Secondary outcomes

  1. Filtration Status (Glomerular Filtration Rate (GFR) < 120 mL/Min/1.73m², Yes/no) After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril

    Filtration status (Glomerular Filtration Rate (GFR) \< 120 mL/min/1.73m²) after 4 weeks of treatment with either empagliflozin added to ramipril or placebo added to ramipril. Filtration status is defined as whether a patient has normal Filtration status (GFR \< mL/min/1.73m², "yes") or not (GFR ≥ mL/min/1.73m², "no"). The pre-specified statistical analysis was not conducted, because data are too sparse in the subgroup of hyperfilterers.

    Time frame: At week 4 and at week 12.

07

Results

Posted Jul 24, 2020

Participant flow

A randomized, double-blinded, placebo-controlled, crossover trial to compare the effect of empagliflozin versus placebo when added to ramipril on reducing glomerular hyperfiltration in patients with type 1 Diabetes mellitus (T1D), Type 2 Diabetes (T2D), or obesity.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneSequence A: 25 mg Empagliflozin / PlaceboSequence B: Placebo / 25 mg Empagliflozin
Started1615
Completed1615
Not completed00
Wash-out Period
Participant flow — Wash-out Period
MilestoneSequence A: 25 mg Empagliflozin / PlaceboSequence B: Placebo / 25 mg Empagliflozin
Started1615
Completed1515
Not completed10
Withdrew: Adverse event10
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneSequence A: 25 mg Empagliflozin / PlaceboSequence B: Placebo / 25 mg Empagliflozin
Started1515
Completed1515
Not completed00

Outcome measures

PrimaryGlomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.

Glomerular filtration rate (GFR) under euglycaemic conditions after 4 weeks of treatment with either empagliflozin added to ramipril or placebo added to ramipril. The pre-specified statistical analysis was not conducted, because data are too sparse in the subgroup of hyperfilterers.

Time frame:
At week 4 and at week 12
Reported as:
Mean · milliliter (mL) /minutes (min) /1.73m²
Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.
milliliter (mL) /minutes (min) /1.73m²25 mg EmpagliflozinPlacebo
Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.124.0 ± 10.61132.5 ± 7.78
SecondaryFiltration Status (Glomerular Filtration Rate (GFR) < 120 mL/Min/1.73m², Yes/no) After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril

Filtration status (Glomerular Filtration Rate (GFR) \< 120 mL/min/1.73m²) after 4 weeks of treatment with either empagliflozin added to ramipril or placebo added to ramipril. Filtration status is defined as whether a patient has normal Filtration status (GFR \< mL/min/1.73m², "yes") or not (GFR ≥ mL/min/1.73m², "no"). The pre-specified statistical analysis was not conducted, because data are too sparse in the subgroup of hyperfilterers.

Time frame:
At week 4 and at week 12.
Reported as:
Count of participants · Participants
Filtration Status (Glomerular Filtration Rate (GFR) < 120 mL/Min/1.73m², Yes/no) After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril
Participants25 mg EmpagliflozinPlacebo
Yes10
No12

Adverse events

Collected over From drug administration until 7 days after the last dose of treatment, up to 91 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
25 mg Empagliflozin0/31 (0%)0/31 (0%)15/31 (48.4%)
Placebo0/30 (0%)2/30 (6.7%)13/30 (43.3%)
Most frequent serious events
Most frequent serious events
Event25 mg EmpagliflozinPlacebo
Intestinal obstructionGastrointestinal disorders0/311/30
Testicular ruptureInjury, poisoning and procedural complications0/311/30
Most frequent other events
Most frequent other events
Event25 mg EmpagliflozinPlacebo
NasopharyngitisInfections and infestations3/317/30
KetosisMetabolism and nutrition disorders6/311/30
HeadacheNervous system disorders3/313/30
CoughRespiratory, thoracic and mediastinal disorders0/313/30
FatigueGeneral disorders3/310/30
ThirstGeneral disorders2/310/30
DizzinessNervous system disorders2/311/30

Baseline characteristics

Full Analysis Set (FAS): The FAS consists of all patients who were randomised, treated with at least one dose of empagliflozin/placebo and provided randomisation baseline (visit 8) and at least one post-randomisation glomerular filtration rate (GFR) measurement.

Age, Continuous
Age, Continuous(Years)Sequence A: 25 mg Empagliflozin / PlaceboSequence B: Placebo / 25 mg EmpagliflozinTotal
Mean26.5 ± 4.227.0 ± 5.026.7 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Sequence A: 25 mg Empagliflozin / PlaceboSequence B: Placebo / 25 mg EmpagliflozinTotal
Female10717
Male6713
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence A: 25 mg Empagliflozin / PlaceboSequence B: Placebo / 25 mg EmpagliflozinTotal
Hispanic or Latino101
Not Hispanic or Latino151429
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence A: 25 mg Empagliflozin / PlaceboSequence B: Placebo / 25 mg EmpagliflozinTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American022
White141125
More than one race000
Unknown or Not Reported000
Glomerular filtration rate (GFR) at baseline
Glomerular filtration rate (GFR) at baseline(milliliter (mL) /minutes (min) /1.73m²)Sequence A: 25 mg Empagliflozin / PlaceboSequence B: Placebo / 25 mg EmpagliflozinTotal
Mean113.6 ± 9.4115.7 ± 14.0114.6 ± 11.6
08

Study locations

1 site
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
09

References and documents

Publications

  • Lytvyn Y, Kimura K, Peter N, Lai V, Tse J, Cham L, Perkins BA, Soleymanlou N, Cherney DZI. Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition. Circulation. 2022 Aug 9;146(6):450-462. doi: 10.1161/CIRCULATIONAHA.122.059150. Epub 2022 Jul 11. PubMed 35862082 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Dec 2017, 19 months.

Results were first posted in Jul 2020, 2 years 7 months after primary completion.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 19 months is close to that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2015
First posted
Dec 17, 2015
StartActual
May 10, 2016
Primary completionActual
Dec 19, 2017
CompletionActual
Jul 2, 2019
Results first posted
Jul 24, 2020
Last update
Jul 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02632747
Responsible party
Sponsor
First posted
Dec 17, 2015
Start date
May 10, 2016
Primary completion
Dec 19, 2017
Completion
Jul 2, 2019
Results posted
Jul 24, 2020
Last update
Jul 24, 2020

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Ramipril

Start the discussion